To determine if galectin-3 could be used as a prognostic indicator in this cohort, we performed an ROC curve analysis of patients with severe HF and determined that a pre-operative galectin-3 cutoff value of 35.4 ng/ml predicted higher mortality following LVAD placement (66.7 % specificity, 84.2 % sensitivity, p = 0.025) (Fig. 3a). The gene discussed is LGALS3; the disease is hydrops fetalis.